Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma

DISEASE CHARACTERISTICS:

* Diagnosis of multiple myeloma

  * Relapsed or refractory disease

PATIENT CHARACTERISTICS:

* ECOG performance status 0-2
* Life expectancy ≥ 3 months
* ANC ≥ 1.0 x 10\^9/L (no granulocyte growth factor support, e.g., G-CSF or GM-CSF allowed)
* Platelet count ≥ 100 x 10\^9/L (erythropoietin allowed, no platelet or RBC transfusion within the past 2 weeks)
* Hemoglobin ≥ 8 g/dL (erythropoietin allowed, no platelet or RBC transfusion within the past 2 weeks)
* Creatinine clearance ≥ 30 mL/min
* AST or ALT ≤ 2.5 times upper limit of normal (ULN)
* Total bilirubin ≤ 1.5 times ULN
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 3 months after completion of study treatment
* LVEF ≥ 45% by MUGA or ECHO
* Symptomatic neuropathy \< grade 2
* No known history of HIV
* No active or serious infection, medical or psychiatric illness that would preclude study participation
* No active hepatitis B or C infection
* No other prior or concurrent malignancy except for adequately treated basal cell or squamous cell carcinoma of the skin, in situ malignancy, low-risk prostate cancer after curative therapy, or other cancer for which the patient has been disease-free for ≥ 3 years
* No history of hypersensitivity reaction to bortezomib or any of its components (boron, mannitol), vorinostat, doxorubicin hydrochloride, or any of the components of PLD
* No serum potassium ≤ 3.0 or serum magnesium ≤ 1.6 that cannot be corrected with supplementation are excluded
* Patients must have adequate cardiovascular function, defined by all of the following:

  * No EKG evidence of active, clinically significant conduction system abnormalities
  * No EKG evidence of QTc prolongation \> grade 2
* NOTE: Any EKG abnormality at screening has to be documented by the investigator as not medically significant.

PRIOR CONCURRENT THERAPY:

* No limit to number of prior treatment regimens
* At least 30 days since prior therapy and recovered
* At least 3 months since prior autologous stem cell transplantation and recovered
* Prior allogeneic stem cell or bone marrow transplantation allowed provided the following criteria are met:

  * More than 1 year since transplantation
  * No longer receiving immunosuppressive therapy or treatment for graft-versus-host disease (GVHD) prophylaxis
  * No active GVHD
  * No active, uncontrolled infections
* No major surgery within the past 3 weeks
* No prior anthracycline dose \> 360 mg/m\^2 for doxorubicin hydrochloride (including pegylated liposomal doxorubicin hydrochloride \[PLD\]) or 720 mg/m\^2 for epirubicin hydrochloride
* No prior or concurrent histone deacetylase inhibitor (e.g., valproic acid)
* No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF) during course 1
* No other concurrent investigational or anticancer agent